Bibliography
- Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 2008;22:621-41
- Mohler KM, Torrance DS, Smith CA, et al. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethalendotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61
- Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf 2012;11:121-39
- Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol 2011;5:1563-71
- Paul C, Stalder JF, Thaçi D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2012;26:448-55
- Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, et al. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther 2010;10:301-7
- Tarifas vigentes por asistencia sanitaria para atención primaria ejercicio 2009. Conselleria Sanitat Generalitat Valenciana
- Müller-Ladner U, Flipo RM, Vincendon P, et al. Comparison of patient satisfaction with two different etanercept delivery systems: a randomised controlled study in patients with rheumatoid arthritis. Z Rheumatol 2012;71:890-9